July 20, 2018
TCS positioned as a leader in Life Sciences R and D BPO Services in IDC Marketscape
Tata Consultancy Services’ advanced drug development platform based on cognitive computing, AI and automation, and broad service offerings cited as key strengths
NEW YORK | MUMBAI: Tata Consultancy Services (TCS), (BSE: 532540, NSE: TCS), a leading global IT services, consulting and business solutions organisation, has been recognised as a Leader in the IDC MarketScape for Worldwide Life Sciences R&D BPO Services 2018.1
The report credits TCS’ leadership to strong discovery research, clinical data management, and pharmacovigilance BPO services. Among other strengths, the report cites TCS’ innovation offering, the Advanced Drug Development platform, which provides BPaaS solutions based on cognitive computing, artificial intelligence (AI), and robotics automation.
Debashis Ghosh, president, life sciences and healthcare, TCS, said, “In a Business 4.0 world, life sciences companies are embracing digital technologies to drive faster clinical innovation, increase the returns from their R&D investments and meet the demands of an ever changing regulatory landscape. This recognition by IDC is a reflection of TCS’ deep understanding of the life sciences value chain and ability to align our strategy and offerings with our customers’ current and future needs.”
TCS partners with leading life sciences companies to drive innovation and reimagine their R&D processes by leveraging next generation platforms and emerging technologies. The company offers a full set of services spanning consulting, cognitive business operations and digital transformation services, as well as platform solutions in the life sciences sector.
TCS’ robust solutions use a combination of artificial intelligence, cognitive computing capabilities, robotic process automation and cloud to fully digitise the drug development process. The company’s genomics and translational research offerings deliver differentiated value to life sciences companies by combining bioinformatics analysis and DNA sequencing lab capabilities for emerging genomics-driven R&D initiatives.
Alan S Louie, research director, IDC health insights life science R&D strategies and technology, said, “While a variety of new business models are being considered and evaluated, companies are concurrently looking to better exploit both technological innovation and best practices from outside of the industry. With a focus on technology, it is clear that this paradigm shift has been long in the making. TCS' Business 4.0 thought leadership framework, strong technical focus and broad service offerings make it a preferred partner to address customers’ R&D BPO needs.”
Mr Ghosh added, “Our deep industry expertise, contextual knowledge, digital technology expertise and advanced platform solutions enable enhanced patient centricity, drive better insights and improve productivity across the R&D value chain, resulting in higher business value for our customers.”
1 IDC MarketScape: Worldwide Life Science R&D BPO Services 2018 Vendor Assessment by Alan S. Louie, Ph.D., June 2018